{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:39:44Z","timestamp":1763415584726,"version":"3.45.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with lower urinary tract symptoms due to benign prostatic enlargement (LUTS\/BPE), assessing patient risk of disease progression is important to determine if treatment with 5-alpha-reductase inhibitors (5ARIs) is warranted. Clinical trials and guidelines have identified risk factors for disease progression, which affects subsequent treatment decision making; however, real-world clinical practices may differ. This non-interventional, cross-sectional study examined the management of patients with LUTS\/BPE at risk of disease progression receiving 5ARIs by urologists from Spain and Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Urologists were randomly recruited and completed an online questionnaire comprising multiple-choice, open-ended ranking and rating questions on their clinical approach in patients with LUTS\/BPE receiving 5ARIs. Urologists also provided patient record forms for two recent patients treated with 5ARIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Spain and Brazil (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100 each), 66% and 75% of urologists, respectively, assessed patients for their risk of LUTS\/BPE progression. The most frequent parameters used to assess risk of progression were: post-void residual volume (PVR: 79% Spain, 83% Brazil), prostate volume (PV: 78% Spain, 82% Brazil), and International Prostate Symptom Score (IPSS: 79% Spain, 79% Brazil). These were also the most frequent parameters considered before initiating 5ARIs: PVR (60% Spain, 78% Brazil); PV (87% Spain, 89% Brazil); and IPSS (66% Spain, 61% Brazil). Thresholds used to assess risk factors of disease progression were generally higher than recommended by clinical guidelines. Reasons for initiating 5ARIs included: to achieve sustained symptom relief (70% Spain, 71% Brazil) and reduce the risk of progression (63% Spain, 66% Brazil). Impact on sexual function was a barrier to 5ARI initiation (46% Spain, 67% Brazil).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most urologists in Spain and Brazil recognized the benefits of assessing the risk of disease progression in patients with LUTS\/BPE. Many urologists reported assessing fewer risk factors and using higher thresholds than recommended by international guidelines, highlighting the need for ongoing medical education.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01966-6","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:46:44Z","timestamp":1763412404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of patients with lower urinary tract symptoms due to benign prostatic enlargement at risk of progression treated with 5-alpha-reductase inhibitors: examining real-world clinical practice in Spain and Brazil"],"prefix":"10.1186","volume":"25","author":[{"given":"Juan Manuel","family":"Palacios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratiksha","family":"Kapse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio Augusto","family":"Averbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Budia","family":"Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo Souza Lima","family":"da Costa Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suryakant","family":"Somvanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1966_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","volume":"5","author":"EH Kim","year":"2018","unstructured":"Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5:28\u201332. https:\/\/doi.org\/10.1016\/j.ajur.2017.11.005.","journal-title":"Asian J Urol"},{"key":"1966_CR2","unstructured":"Ng M, Krishna MB, Baradhi KM. Benign Prostatic Hyperplasia. StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558920\/. StatPearls. 2022.\u00a0Accessed 23 Jul 2025."},{"issue":"Suppl 5","key":"1966_CR3","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1002\/nau.24076","volume":"38","author":"R Bosch","year":"2019","unstructured":"Bosch R, Abrams P, Averbeck MA, Finazzi Agr\u00f3 E, Gammie A, Marcelissen T, et al. Do functional changes occur in the bladder due to bladder outlet obstruction? - ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S56-65. https:\/\/doi.org\/10.1002\/nau.24076.","journal-title":"Neurourol Urodyn"},{"key":"1966_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/nau.23418","volume":"37","author":"MA Averbeck","year":"2018","unstructured":"Averbeck MA, De Lima NG, Motta GA, Beltrao LF, Abboud Filho NJ, Rigotti CP, et al. Collagen content in the bladder of men with LUTS undergoing open prostatectomy: a pilot study. Neurourol Urodyn. 2018;37:1088\u201394. https:\/\/doi.org\/10.1002\/nau.23418.","journal-title":"Neurourol Urodyn"},{"key":"1966_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/ju.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206:806\u201317. https:\/\/doi.org\/10.1097\/ju.0000000000002183.","journal-title":"J Urol"},{"key":"1966_CR6","unstructured":"European Association of Urology EAU Guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). Arnhem. 2024; https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2024.pdf. Accessed 11 Sept 2025."},{"key":"1966_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr., Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387\u201398. https:\/\/doi.org\/10.1056\/NEJMoa030656.","journal-title":"N Engl J Med"},{"key":"1966_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and Tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the combat study. Eur Urol. 2010;57:123\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.035.","journal-title":"Eur Urol"},{"key":"1966_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/s0022-5347(05)00708-1","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422\u20136. https:\/\/doi.org\/10.1016\/s0022-5347(05)00708-1. discussion 6\u20137.","journal-title":"J Urol"},{"key":"1966_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14250","volume":"75","author":"B Mi\u00f1ana","year":"2021","unstructured":"Mi\u00f1ana B, Molero JM, Agra Rol\u00e1n A, Mart\u00ednez-Fornes MT, Cuervo Pinto R, Lorite Mingot D, et al. Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain. Int J Clin Pract. 2021;75:e14250. https:\/\/doi.org\/10.1111\/ijcp.14250.","journal-title":"Int J Clin Pract"},{"key":"1966_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5489\/cuaj.3058","volume":"10","author":"M Bishr","year":"2016","unstructured":"Bishr M, Boehm K, Trudeau V, Tian Z, Dell\u2019Oglio P, Schiffmann J, et al. Medical management of benign prostatic hyperplasia: results from a population-based study. Can Urol Assoc J. 2016;10:55\u20139. https:\/\/doi.org\/10.5489\/cuaj.3058.","journal-title":"Can Urol Assoc J"},{"key":"1966_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5527\/wjn.v12.i1.1","volume":"12","author":"J Yaxley","year":"2023","unstructured":"Yaxley J, Yaxley W. Obstructive uropathy - acute and chronic medical management. World J Nephrol. 2023;12:1\u20139. https:\/\/doi.org\/10.5527\/wjn.v12.i1.1.","journal-title":"World J Nephrol"},{"key":"1966_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/s0090-4295(02)01905-2","volume":"60","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434\u201341. https:\/\/doi.org\/10.1016\/s0090-4295(02)01905-2.","journal-title":"Urology"},{"key":"1966_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bju.13033","volume":"116","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed-dose combination of dutasteride and Tamsulosin treatment (Duodart\u00ae) compared with watchful waiting with initiation of Tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-na\u00efve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116:450\u20139. https:\/\/doi.org\/10.1111\/bju.13033.","journal-title":"BJU Int"},{"key":"1966_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.euf.2022.07.004","volume":"9","author":"S Gravas","year":"2023","unstructured":"Gravas S, Palacios-Moreno JM, Thompson D, Concas F, Kamola PJ, Roehrborn CG, et al. Understanding treatment response in individual profiles of men with prostatic enlargement at risk of progression. Eur Urol Focus. 2023;9:178\u201387. https:\/\/doi.org\/10.1016\/j.euf.2022.07.004.","journal-title":"Eur Urol Focus"},{"key":"1966_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41391-023-00731-w","volume":"27","author":"S Gravas","year":"2024","unstructured":"Gravas S, Manuel-Palacios J, Chavan C, Roehrborn CG, Oelke M, Averbeck MA, et al. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression. Prostate Cancer Prostatic Dis. 2024;27:469\u201377. https:\/\/doi.org\/10.1038\/s41391-023-00731-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1966_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/andr.12353","volume":"5","author":"G Corona","year":"2017","unstructured":"Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. Sexual dysfunction in subjects treated with inhibitors of 5\u03b1-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5:671\u20138. https:\/\/doi.org\/10.1111\/andr.12353.","journal-title":"Andrology"},{"key":"1966_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.urology.2017.08.025","volume":"118","author":"AK Sokhal","year":"2018","unstructured":"Sokhal AK, Sankhwar S, Goel A, Singh K, Kumar M, Purkait B, et al. A prospective study to evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active men treated for benign prostatic hyperplasia by alpha-blockers. Urology. 2018;118:92\u20137. https:\/\/doi.org\/10.1016\/j.urology.2017.08.025.","journal-title":"Urology"},{"key":"1966_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203479","volume":"13","author":"JH Kim","year":"2018","unstructured":"Kim JH, Baek MJ, Sun HY, Lee B, Li S, Khandwala Y, et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS ONE. 2018;13:e0203479. https:\/\/doi.org\/10.1371\/journal.pone.0203479.","journal-title":"PLoS ONE"},{"key":"1966_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34427","volume":"4","author":"SR Bauer","year":"2021","unstructured":"Bauer SR, Walter LC, Ensrud KE, Suskind AM, Newman JC, Ricke WA, et al. Assessment of frailty and association with progression of benign prostatic hyperplasia symptoms and serious adverse events among men using drug therapy. JAMA Netw Open. 2021;4:e2134427. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.34427.","journal-title":"JAMA Netw Open"},{"key":"1966_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"G Gandaglia","year":"2013","unstructured":"Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432\u201341. https:\/\/doi.org\/10.1111\/bju.12118.","journal-title":"BJU Int"},{"key":"1966_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.euf.2018.03.007","volume":"4","author":"A Sebastianelli","year":"2018","unstructured":"Sebastianelli A, Gacci M. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus. 2018;4:25\u20137. https:\/\/doi.org\/10.1016\/j.euf.2018.03.007.","journal-title":"Eur Urol Focus"},{"key":"1966_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/j.1742-1241.2010.02463.x","volume":"64","author":"M Emberton","year":"2010","unstructured":"Emberton M. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract. 2010;64:1425\u201335. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02463.x.","journal-title":"Int J Clin Pract"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01966-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:46:46Z","timestamp":1763412406000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01966-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01966-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A central independent review board (Pearl Independent Institution Review Board) considered that the research had no risk or minimal risk to participants and was exempt from most of the requirements of the Federal Policy for the Protection of Human Subjects. Written informed consent was obtained from all participants. This study was conducted according to the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study complied with all applicable laws in the relevant countries regarding participant privacy. Urologists completed consent forms before study participation. All patient data were de-identified so informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the time of study, JMP and PK were employed by and held financial equities in GSK. VC, and SS are employed by and hold financial equities in GSK. MAA, ABA, DSLdCC, and FP reported no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}